Stock of Enliven Therapeutics, Inc. (ELVN) is gaining 10 percent on Thursday morning after the company announced updated positive data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with previously treated chronic myeloid leukemia.
The company's shares are currently trading at $40.99 on the Nasdaq, gaining 10.77 percent in the latest session. The stock opened at $45.52. Over the past 12 months, the shares have traded between $14.78 and $48.53.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.